Back to Report Store Home

Frontier Pharma: Orphan and Rare Dermatological Diseases – First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

  • Published: Sep-2018
  • Report Code: GBIHC483MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Neglected Therapy Area with High Levels of Genericization

2.2 Diverse Pipeline Demonstrates Potential to Address Unmet Needs

2.3 Increase in Strategic Consolidations in Recent Years

3 The Case for Innovation

3.1 Growing Opportunities for Biologic Products

3.2 Diversification of Molecular Targets

3.3 Innovative First-in-Class Product Developments Remain Attractive

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation

3.5 Sustained Innovation in Orphan and Rare Dermatological Diseases

3.6 GBI Research Report Guidance

4 Clinical and Commercial Landscape

4.1 Overview of the Dermatology Market

4.2 Overview of Orphan and Rare Diseases

4.2.1 Overview of Systemic Sclerosis (Scleroderma)

4.2.2 Overview of Alopecia

4.2.3 Overview of Epidermolysis Bullosa

4.2.4 Overview of Pemphigus Vulgaris

4.2.5 Overview of Vitiligo

4.2.6 Overview of Cutaneous Lupus Erythematosus

4.3 Symptoms

4.3.1 Systemic sclerosis

4.3.2 Alopecia

4.3.3 Epidermolysis bullosa

4.3.4 Pemphigus Vulgaris

4.3.5 Vitiligo

4.3.6 Cutaneous Lupus Erythematosus

4.4 Diagnosis

4.4.1 Systemic sclerosis

4.4.2 Alopecia

4.4.3 Epidermolysis bullosa

4.4.4 Pemphigus Vulgaris

4.4.5 Vitiligo

4.4.6 Cutaneous Lupus Erythematosus

4.5 Etiology

4.5.1 Systemic Sclerosis

4.5.2 Alopecia

4.5.3 Epidermolysis Bullosa

4.5.4 Pemphigus Vulgaris

4.5.5 Vitiligo

4.5.6 Cutaneous Lupus Erythematosus

4.6 Pathophysiology

4.6.1 Systemic Sclerosis

4.6.2 Alopecia

4.6.3 Epidermolysis Bullosa

4.6.4 Pemphigus Vulgaris

4.6.5 Vitiligo

4.6.6 Cutaneous Lupus Erythematosus

4.7 Epidemiology

4.7.1 Systemic sclerosis

4.7.2 Alopecia

4.7.3 Epidermolysis Bullosa

4.7.4 Pemphigus Vulgaris

4.7.5 Vitiligo

4.7.6 Cutaneous Lupus Erythematosus

4.8 Co-morbidities and Complications

4.8.1 Systemic Sclerosis

4.8.2 Alopecia

4.8.3 Epidermolysis Bullosa

4.8.4 Pemphigus Vulgaris

4.8.5 Vitiligo

4.8.6 Cutaneous Lupus Erythematosus

4.9 Treatment

4.9.1 Systemic Sclerosis

4.9.2 Alopecia

4.9.3 Epidermolysis Bullosa

4.9.4 Pemphigus Vulgaris

4.9.5 Vitiligo

4.9.6 Cutaneous Lupus Erythematosus

4.10 Overview of Marketed Products

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.2.1 Overall Pipeline

5.2.2 Pipeline by Key Indications

5.3 Pipeline by Molecular Target

5.3.1 Overall Pipeline

5.3.2 Pipeline for Key Indications

5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class

5.6 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Stage of Development, Molecule Type and Molecular Target Class

5.7 Ratio of First-in-Class Programs to First-in-Class Molecular Targets by Stage of Development, Molecule Type and Molecular Target Class

5.8 List of All Pipeline Programs

6 Signaling Network, Disease Causation and Innovation Alignment

6.1 Complexity of Signaling Networks in Orphan and Rare Dermatological Diseases

6.2 Signaling Pathways and First-in-Class Molecular Target Integration

6.3 First-in-Class Molecular Target Matrix Assessment

7 First-in-Class Molecular Target Evaluation

7.1 Pipeline Programs Targeting XXX

7.2 Pipeline Programs Targeting XXX

7.3 Pipeline Programs Targeting XXX

7.4 Pipeline Programs Targeting XXX

7.5 Pipeline Programs Targeting XXX

7.6 Pipeline Programs Targeting XXX

7.7 Pipeline Programs Targeting XXX

7.8 Pipeline Programs Targeting XXX

7.9 Pipeline Programs Targeting XXX

7.10 Pipeline Programs Targeting XXX

7.11 Pipeline Programs Targeting XXX

7.12 Pipeline Programs Targeting XXX

8 Strategic Consolidations

8.1 Industry-wide First-in-Class Deals

8.2 Licensing Deals

8.2.1 Deals by Region, Value and Year

8.2.2 Deals by Key Indication and Value

8.2.3 Deals by Stage of Development and Value

8.2.4 Deals by Molecule Type and Molecular Target

8.2.5 List of Deals with Disclosed Deal Values

8.3 Co-development Deals

8.3.1 Deals by Region, Value and Year

8.3.2 Deals by Indication and Value

8.3.3 Deals by Stage of Development and Value

8.3.4 Deals by Molecule Type and Molecular Target

8.3.5 List of Deals with Disclosed Deal Values

8.4 First-in-Class Programs with and without Prior Licensing or Co-development Deal Involvement

9 Appendix

9.1 References

9.2 Abbreviations

9.3 Pipeline Disease List

9.4 Methodology

9.4.1 Data Integrity

9.4.2 Innovative and Meaningful Analytical Techniques and Frameworks

9.4.3 Evidence Based Analysis and Insight

9.5 Secondary Research

9.5.1 Market Analysis

9.5.2 Pipeline Analysis

9.5.3 Licensing and Co-development Deals

9.6 Contact Us

9.7 Disclaimer

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards